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Introduction: Recently, a new lung adenocarcinoma classiﬁcation 
scheme was published. The prognostic value of this new classiﬁ-
cation has not been elaborated together with the value of imaging 
biomarkers including computed tomography (CT) and positron emis-
sion tomography (PET).
Methods: We reviewed pathologic specimens and imaging charac-
teristics of primary tumors from 723 consecutive patients who under-
went surgical resection for lung adenocarcinoma. On pathology, the 
predominant histologic subtype and pattern group were quantiﬁed. 
Tumor-shadow disappearance ratio (TDR) on CT and maximum 
standardized uptake value (SUVmax) on PET were assessed. The 
relationships between those variables and survival (overall survival 
[OS] and disease-free survival) were analyzed by using Kaplan–
Meier curves and Cox regression analyses.
Results: The median follow-up period was 3.8 years. There were 137 
patients (19%) with recurrence and 167 patients (23%) with metas-
tasis after surgical resection. Among 723 patients, 35 patients (4.8%) 
had adenocarcinoma in situ, 34 patients (4.7%) had minimally inva-
sive adenocarcinoma, 125 patients (17.3%) had lepidic predominant, 
314 patients (43.4%) had acinar predominant, 65 patients (9.0%) 
had papillary predominant, 23 patients (3.2%) had micropapillary 
predominant, 113 patients (15.6%) had solid predominant, and 
14 patients (1.9%) had variant adenocarcinomas. OS and disease-
free survival rates were signiﬁcantly different according to TDR on 
CT and SUVmax on PET, predominant subtypes, and pattern groups. 
On multivariate analysis, the SUVmax (p < 0.001), TDR (p = 0.038), 
and pattern group (p = 0.015) were independent predictors of OS.
Conclusions: TDR on CT, SUVmax on PET, and the new histo-
logic classiﬁcation schemes appear to be promising parameters for 
the prognostic stratiﬁcation of patients with lung adenocarcinomas, 
allowing for the triage of patients who necessitate further staging 
workup and adjuvant therapy.
Key words: Lung adenocarcinoma, Survival, Histology, Positron 
emission tomography, Computed tomography, Ground-glass opacity.
(J Thorac Oncol. 2015;10: 1785–1794)
Lung cancer is the leading cause of cancer death in many coun-tries, and non–small-cell lung cancer (NSCLC) accounts 
for approximately 80% of all lung cancers.1 Adenocarcinoma 
is the most common histologic type of NSCLC.2 Until now, 
the single most important prognostic factor in patients with 
NSCLC, including adenocarcinoma, has been tumor stage.3 
However, there is a wide spectrum of tumor behavior that can 
be predicted by recognizing well-known prognostic factors, 
such as tumor-node-metastasis (TNM) stage at the time of ini-
tial diagnosis.4 As for early-stage lung adenocarcinomas, sur-
gical resection is the treatment of choice; nevertheless, even 
after curative surgical resection, the 5-year overall survival 
(OS) rate in patients with stage 1 lung adenocarcinoma is 
approximately 60% to 70%, and 30% to 40% of these patients 
eventually have recurrent disease, which is the most common 
cause of treatment failure after resection.5,6 Therefore, we 
need to identify robust prognostic biomarkers to help predict 
which patients with operable lung cancer are at the highest 
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risk for recurrent disease and, consequently, are candidates for 
more aggressive surveillance or adjuvant therapy.
Recently, a new lung adenocarcinoma classiﬁcation 
scheme was published by the International Association for the 
Study of Lung Cancer (IASLC)/American Thoracic Society 
(ATS)/and European Respiratory Society (ERS),7 and the 
prognostic value of the new classiﬁcation system with respect 
to survival and recurrence has been investigated in several 
studies.8–14 Meanwhile, there have been many efforts to stratify 
patients with lung adenocarcinoma using noninvasive surro-
gate biomarkers, such as imaging tools.15–20 Although several 
studies have reported results comparing the prognostication 
capabilities of computed tomography (CT), positron emis-
sion tomography (PET), and histopathologic ﬁndings,20–22 the 
new classiﬁcation system for lung adenocarcinomas has not 
been elaborated together with those prognostic factors. In this 
article, we focus on the prognostic predictive value of imaging 
biomarkers such as tumor-shadow disappearance ratio (TDR) 
on CT and maximum standardized uptake value (SUVmax) 
on 18F-ﬂuoro-2-deoxyglucose (FDG)-PET/CT in patients with 
completely resected stages I–III lung adenocarcinomas, and 




This single institution retrospective study was approved 
by our institutional review board with a waiver of informed con-
sent. Between September 2003 and August 2011, we identiﬁed 
859 consecutive patients who underwent complete resection 
of adenocarcinoma with mediastinal lymph node dissection 
at Samsung Medical Center (Seoul, Korea). All patients were 
treated with surgery alone or surgery plus postsurgical adju-
vant therapy. Sixty-eight patients were excluded because of the 
following prognosis-related factor: the presence of microme-
tastasis at the time of surgery (n = 25) and the presence of 
another cancer (n = 43). Another 68 patients were excluded 
because of radiologically or pathologically related factors such 
as insufﬁcient pathologic slides for the evaluation of the whole 
tumor (n = 39), poor CT image  quality (n = 23), and limited 
tumor evaluation due to the presence of concurrent extensive 
inflammation or lung infarction (n = 6). Thus, 723 patients 
(372 males, 351 females; median age, 60 years) were included 
in the present analysis. All cases were reviewed according to 
the International Multidisciplinary Lung Adenocarcinoma 
Classiﬁcation criteria7 and were staged according to the 7th 
edition of the TNM classiﬁcation for lung cancer.21,22
Imaging and Analysis
Imaging characteristics of each primary lung tumor were 
evaluated using chest CT and the PET component of PET/CT. 
PET/CT and chest CT were obtained within 1 month (mean: 
17.5 days; median: 13.5 days) of each study. FDG PET/CT 
images were acquired using a PET/CT device (Discovery LS; 
GE Healthcare, Milwaukee, WI), which consisted of a PET 
scanner (Advance NXi; GE Healthcare, Milwaukee, WI) and an 
eight-section CT scanner (Light-Speed Plus; GE Healthcare). 
The imaging methods used are described in detail in a previ-
ous report.20
Dedicated chest CT images were obtained with an 
8- (LightSpeed Ultra, GE Healthcare) or 16-detector row 
(LightSpeed16, GE Healthcare) CT scanner. CT images were 
obtained using the following parameters: detector collimation, 
0.625 mm; ﬁeld of view, 34.5 cm; beam pitch, 1.35 or 1.375; 
gantry speed, 0.6 seconds per rotation; 120 kVp; 150 to 200 
mA; and section thickness, 1.25 mm for transverse images. All 
imaging data were reconstructed using soft tissue algorithms.
A nuclear medicine physician with 11 years of expe-
rience in PET/CT interpretation and who was unaware of 
clinical and pathologic data evaluated all PET images. For 
semiquantitative analysis of FDG uptake, regions of interest 
(ROIs) were placed over the most intense area of FDG accu-
mulation. When nodular FDG uptake could not be assessed 
on PET component images of PET/CT, an ROI was drawn in 
a presumed nodular location by taking into consideration CT 
component images of PET/CT. FDG uptake within the ROIs 
was calculated as SUVmax.
Chest CT data were interfaced directly to a picture 
archiving and communication system (Path-Speed or Centricity 
2.0; GE Healthcare, Mt. Prospect, IL), which displayed all 
image data on two monitors (1536 × 2048 matrix, 8-bit view-
able grayscale, 60-foot-lambert luminescence). The monitors 
were adapted to view both mediastinal (width, 400 HU; level, 
20 HU) and lung (width, 1500 HU; level, −700 HU) window 
images. Two chest radiologists with 7 and 2 years of experience 
in thoracic CT interpretation, respectively, who were unaware 
of the clinical data, PET ﬁndings, and histologic diagnoses ret-
rospectively evaluated the CT scans for nodule size and TDR. 
Nodule size and TDR were assessed by independent observers, 
and discrepancies in evaluation among them were resolved by 
averaging their determined values. For nodule size, the longest 
tumor diameters were measured on lung window images. On 
transverse images, tumor diameters were measured manually 
on picture archiving and communication system monitors using 
electronic measurement tools. In all cases, observers measured 
the maximum dimension of the tumors (maxD) and the larg-
est dimension perpendicular (perD) to the maximum diameter 
(maxD) using both the lung and mediastinal windows. Two 
methods were adopted for simpliﬁed application of TDR and 
its quantiﬁcation.20 First, TDR-4 was deﬁned to divide the TDR 
extent into four categories: 100% (pure ground-glass opacity 
[GGO]), greater than or equal to 50%, greater than or equal to 
25%, and less than 25%. Second, TDR-2 was deﬁned to divide 
the TDR extent into two categories: greater than or equal to 15% 
and less than 15%. The optimal cut-off value for TDR extent was 
calculated using receiver operating characteristic (ROC) curve 
analysis. The optimal cut-off value was determined as the point 
closest to the upper left corner of the ROC curve. Interobserver 
agreement for TDR at CT was calculated by means of intraclass 
correlation coefﬁcient (ICC) on a small group of randomly 
extracted patients. The 95% CIs for the ICC were also estimated.
Pathologic Evaluation
Whole tumor tissue sections were obtained, and each 
section was placed on a slide. Comprehensive histologic 
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TABLE 1. Correlation of Clinicopathologic Variables with Overall and Disease-Free Survival
Characteristic No. of Patients
Overall Survival Disease-Free Survival
No of Events Survival (Yr) pa No of Events Survival (Yr) pa
Age at diagnosisb (years) 0.008 0.382
  ≤62 380 22 8.96 ± 0.12 92 7.22 ± 0.21
  >62 343 35 8.56 ± 0.16 85 7.15 ± 0.22
Sex <0.001 0.039
  Male 372 43 8.40 ± 0.17 99 6.92 ± 0.23
  Female 351 14 9.13 ± 0.11 78 7.43 ± 0.21
OP type <0.001 0.001
  Wedge resection 107 5 7.24 ± 0.16 12 6.76 ± 0.23
  Lobectomy 607 47 8.80 ± 0.11 161 7.01 ± 1.05
  Pneumonectomy 9 5 3.20 ± 0.96 4 3.61 ± 1.05
Tumor stage <0.001 <0.001
  T1a 333 9 9.30 ± 0.80 41 8.35 ± 0.18
  T1b 209 16 8.80 ± 0.18 65 6.73 ± 0.28
  T2a 140 19 7.73 ± 0.33 46 5.85 ± 0.40
  T2b 31 10 4.54 ± 0.51 19 2.64 ± 0.45
  T3a 10 3 3.62 ± 0.58 6 2.12 ± 0.60
Nodal stage <0.001 <0.001
  N0 581 27 9.10 ± 0.90 104 7.80 ± 0.16
  N1 82 16 5.81 ± 0.26 39 4.40 ± 0.32
  N2 60 14 4.21 ± 0.24 34 2.59 ± 0.27
Predominant subtype <0.001 <0.001
  AIS 35 0 - 0 -
  MIA 34 0 - 0 -
  Lepidic 125 3 9.00 ± 0.13 9 8.52 ± 0.23
  Acinar 314 24 8.77 ± 0.16 96 6.61 ± 0.25
  Papillary 65 7 7.50 ± 0.88 24 5.62 ± 0.62
  Micropapillary 23 3 5.11 ± 0.43 7 4.40 ± 0.45
  Solid 113 20 7.37 ± 0.34 38 5.45 ± 0.55
  Variant 14 0 - 2 8.13 ± 0.55
Pattern group <0.001 <0.001
  AIS/MIA/lepidic 194 2 9.48 ± 0.06 16 8.88 ± 0.17
  Acinar/papillary 379 32 8.53 ± 0.17 115 6.22 ± 0.24
  Micropapillary/solid 136 23 7.44 ± 0.29 46 5.44 ± 0.48
Differentiation <0.001 <0.001
  WD 249 2 4.3 ± 0.13 16 4.1 ± 0.12
  MD 340 32 3.7 ± 0.10 115 3.1 ± 0.10
  PD 134 23 2.9 ± 0.14 46 2.4 ± 0.15
TDR-4 categories <0.001 <0.001
  100% (pure GGO) 220 2 9.43 ± 0.10 9 8.96 ± 0.21
  ≥50% 63 4 8.69 ± 0.25 8 8.14 ± 0.32
  ≥25% 174 15 8.75 ± 0.19 56 6.58 ± 0.32
  <25% 266 36 7.92 ± 0.20 104 5.57 ± 0.27
TDR-2 categoriesb <0.001 <0.001
  ≥15% 576 30 9.05 ± 0.09 114 7.62 ± 0.16
  <15% 147 26 6.07 ± 0.09 61 4.40 ± 0.27
SUVmaxb <0.001 <0.001
  ≤9.5 444 19 9.16 ± 0.09 90 7.69 ± 0.17
  >9.5 129 30 6.85 ± 0.35 66 4.50 ± 0.36
Adjuvant therapy <0.001 <0.001
  Yes 271 41 7.74 ± 0.21 147 3.93 ± 0.19
  No 452 15 9.24 ± 0.08 30 8.87 ± 0.13
aLog-rank test.
bAge, TDR-2, and SUVmax measured for ROC analysis were as follows: 62 years, 15%, and 9.5, respectively.
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; WD, well differentiated; MD, moderately differentiated; PD, poorly differentiated; TDR, tumor shadow 
disappearance rate; GGO, ground glass opacity; TDR, tumor shadow disappearance rate; SUVmax, maximum standardized uptake value.
Bold numbers indicate signiﬁcant p values (<0.05).
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subtyping was performed by two pathologists (J. H. and J. Y. 
J., with 18 and 5 years of experience in lung pathology, respec-
tively) together at a multihead microscope. The evaluation was 
carried out according to the criteria of the novel IASLC/ATS/
ERS classiﬁcation,20 quantifying the extent of each histologic 
component (adenocarcinoma in situ [AIS], minimally invasive 
adenocarcinoma [MIA], invasive adenocarcinoma with lep-
idic, acinar, papillary, micropapillary, or solid-predominant 
type, or variant type) to the nearest 5%. Variant adenocarci-
nomas referred to invasive mucinous adenocarcinoma (for-
merly mucinous bronchioloalveolar carcinoma), and colloid, 
fetal, and enteric adenocarcinoma.7 Variant adenocarcinomas 
included in this study were all mucinous adenocarcinomas. 
For each case, histologic subtyping was performed for the 
primary tumor in a semiquantitative manner, with each sub-
type accounted for in 5% increments for a total of 100% for 
each tumor. Next, the most predominant pattern in a mixed 
type adenocarcinoma was deﬁned as the histopathologic sub-
type that constituted the greatest percentage of the tumor. 
The predominant histologic subtypes were stratiﬁed into 
three pattern groups: AIS/MIA/lepidic, acinar/papillary, and 
micropapillary/solid groups. These pattern groups represent 
low, intermediate, and high grades of clinical behavior based 
on architectural grading system of histologic subtype.9,23 The 
existing tumor grade of differentiation categorized into well, 
moderately, or poorly differentiated carcinomas according to 
the World Health Organization criteria based on the extent to 
which the architectural pattern of the tumor resembles normal 
lung tissue and cytologic atypia was also evaluated.24
Well-differentiated carcinoma was deﬁned as a tumor 
formed of well-formed glands, tubules, or acini with cells 
having mildly pleomorphic nuclei. Moderately differentiated 
carcinoma was deﬁned as a tumor showing solid and glandu-
lar growth with cells having moderately pleomorphic nuclei, 
moderately sized nucleoli, and a higher nuclear:cytoplasmic 
ratio. Poorly differentiated adenocarcinoma was deﬁned as a 
tumor almost entirely composed of solid nests or cords of cells 
having very pleomorphic and frequently prominent nucleoli 
with variable amount of cytoplasm.9,23,25,26
Statistical Analysis
Differences in survival rates were compared in terms 
of age, sex, operation type, TNM stage, tumor size, TDR, 
SUVmax, pathologic variance, and treatment using Kaplan–
Meier curves and log-rank tests. The prognostic value of 
SUVmax and TDR was assessed using ROC curves and the 
total area under the curve (AUC). Optimal thresholds were 
determined by calculating minimum balanced error rates. 
Differences in survival rates were also compared in terms of 
TDR and SUVmax at each TNM stage of lung adenocaricnoma 
using log-rank tests. Univariate and multivariate Cox regression 
analyses were used to determine whether any of the clinical or 
treatment-related variables were predictors of OS and disease-
free survival (DFS). Univariate factors with p values less than 
0.05 were included in multivariate analysis. Nomogram for the 
prediction of survival of lung adenocarcinoma patients were 
generated with selected signiﬁcant variables. The validation 
of nomogram was assessed by quantifying the area under the 
ROC curve. For all statistical tests, a p value less than 0.05 
was considered to be statistically signiﬁcant. Statistical analy-
ses were performed using SPSS software (SPSS for Windows, 
version 11.0, 2001; SPSS, Chicago, IL).
RESULTS
Patient Demographics and Histopathologic 
and Radiologic features
We enrolled 351 women (48%) and 372 men (51%; 
median age, 60 years) in this study. The median follow-up 
period was 3.8 years (range: 0.5–9.4 years). There were 137 
recurrences (19%) and 167 metastases (23%) after surgical 
resection. The clinicopathologic characteristics and imag-
ing biomarkers of the 723 patients included in this study are 
summarized in Table 1. The relationship between imaging 
biomarkers including TDR at CT or SUVmax at PET and his-
tologic subtypes are expressed in Table 2.
A high level of interobserver agreement was demon-
strated for TDR at CT (ICC: 0.993; 95% CI: 0.983, 0.997).
Survival Analyses
The correlations between clinicopathologic variables, 
OS, and DFS in 723 patients with adenocarcinoma are shown 
in Table 1. On ROC analyses, the optimal cutoff values for 
age, TDR, and SUVmax for patient survival were 62 years, 
15%, and 9.5, respectively.
Patients 62 years old or younger had longer OS than 
those older than 62 years (p = 0.008). Mean DFS was also pro-
longed in younger patients, but this difference was not statisti-
cally signiﬁcant (p = 0.382). Clinical factors associated with 
both prolonged OS and DFS were female sex (p < 0.001 and 
p = 0.039, respectively), lobectomy as the operative type (both 
p < 0.001) and tumor and nodal stages (all p < 0.001), and a 
history of adjuvant chemotherapy was a negative predictor of 
OS and DFS (both p < 0.001).
The predominant histologic subtype was also associ-
ated with OS and DFS (both p < 0.001). Patients with AIS 
and MIA had no tumor recurrence or metastases. Among 
TABLE 2. Relationship Between the Predominant Histologic 
Subtypes and Imaging Biomarkers
Predominant 
Subtype
No. of  
Patients TDRa
No. of  
Patients SUVmaxa
AIS 35 95.0 ± 18.9 23 0.7 ± 1.9
MIA 34 97.7 ± 4.5 22 0.7 ± 0.8
Lepidic 125 81.4 ± 27.3 98 1.8 ± 2.6
Acinar 314 38.1 ± 28.4 259 6.2 ± 7.6
Papillary 65 32.0 ± 23.4 52 7.2 ± 4.5
Micropapillary 23 26.4 ± 19.6 18 7.9 ± 3.2
Solid 113 24.2 ± 21.9 87 10.7 ± 5.5
Variants 14 34.1 ± 20.6 14 4.1 ± 2.8
Total 723 47.9 ± 35.0 573 6.2 ± 6.7
aData are means ± standard deviation.
AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; TDR, 
tumor shadow disappearance rate.
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patients with invasive adenocarcinoma, those with lepidic-
predominant adenocarcinoma had the most favorable out-
comes, followed by predominant acinar, papillary, solid, and 
micropapillary specimens. The pattern groups, which were 
stratiﬁed according to the predominant histologic subtype, 
were found to be a signiﬁcant predictor of OS and DFS (both 
p < 0.001). OS and DFS curves for patient groups accord-
ing to the predominant histologic subtype and pattern group 
are shown in Figure 1. Histologic differentiation was also a 
signiﬁcant predictor of OS (p < 0.001) and DFS (p < 0.001). 
Moderately differentiated tumors were the most frequent type 
and patients with well-differentiated tumors had the most 
favorable outcomes.
OS and DFS curves stratiﬁed by TDR-4, TDR-2, and 
SUVmax are shown in Figure 2. Both TDR-4 and TDR-2 
were signiﬁcantly associated with OS and DFS (all p < 0.001). 
Particularly on TDR-4 analysis, DFS increased proportion-
ally with decreases in the TDR-4 value. Increases in SUVmax 
> 9.5 on PET CT were signiﬁcantly associated with shorter 
OS and DFS (both p < 0.001).
In patients with stage I lung adenocarcinoma, histologic 
subtypes and radiologic features including TDR-4, TDR-2, 
and SUVmax were found to be signiﬁcant predictors of DFS 
(all p < 0.001) and OS (p < 0.001, p = 0.010, p = 0.008, and 
p < 0.001, respectively). In patients with stage II or IIIA dis-
ease, TDR-2 and SUVmax were signiﬁcant predictors of OS 
(p = 0.043 and p = 0.038, respectively). However, these were 
not signiﬁcantly associated with DFS (p = 0.318 and p = 0.273, 
respectively), and histologic subtypes were not signiﬁcantly 
related to OS or DFS (p = 0.655 and p = 0.813, respectively).
Multivariate analysis was carried out using two differ-
ent models (Table 3). In the ﬁrst model, the predominant his-
tologic subtype was included with other clinicoradiologic 
variables. Patient age (p = 0.040), sex (p = 0.007), nodal stage 
(p = 0.004), and SUVmax (p < 0.001) appeared to be indepen-
dent prognostic predictors for OS in this model. In the second 
fIGURE 1. Kaplan–Meier survival curves for (A, C) overall and (B, D) disease-free survival according to (A, B) pattern group, 
and (C, D) predominant subtype.
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model, the pattern group was included for analysis instead of 
the predominant histologic subtype. Sex (p = 0.004), tumor 
stage (p = 0.048), nodal stage (p = 0.005), pattern group 
(p = 0.015), SUV max (p < 0.001), and TDR-2 (p = 0.038) 
appeared to be independent prognostic predictors for OS. Pattern 
group was also a signiﬁcant predictive factor for DFS (p = 0.044). 
fIGURE 2. Kaplan–Meier survival curves for (A, C, E) overall and (B, D, F) disease-free survival according to (A, B) SUV max,  
(C, D) TDR-4, and (E, F) TDR-2. TDR, tumor shadow disappearance rate.
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A history of adjuvant therapy was shown to be a negative prog-
nostic predictor for DFS in both models (both p < 0.001).
Creation of Nomogram
Nomogram for predicting the probability of survival at 
3- and 6-year was constructed with seven variables (Fig. 3). 
For the performance validation of nomograms, patients were 
grouped into tertiles according to total points assigned by the 
nomogram (1st tertile, 0–76.5; 2nd tertile, 76.5–144; 3rd ter-
tile, 144–336). Figure 4 showed observed survival curve for 
the three risk groups. The tertiles of the nomogram showed 
different observed survival probabilities. The AUC was high 
for predicting the survival probability. Total AUCs for pre-
dicting 3-, 6-, and 9-year survival by the time-dependent 
ROC curve were 0.90 (95% CI: 0.85–0.95), 0.89 (95% CI: 
0.80–0.97), and 0.92 (95% CI: 0.83–1.00), respectively.
DISCUSSION
The prognosis for lung adenocarcinoma varies even in 
the early stages of the disease, and more than 30% of patients 
who undergo complete resection experience recurrence.5,6 In 
recent years, many studies have looked at adjuvant chemo-
therapy for patients with early stage lung cancer and a high 
risk of poor outcomes to improve survival.27,28 Thus, identify-
ing key prognostic factors for recurrence may help determine 
which patients are most in need of additional therapy.
The prognostic value of the new classiﬁcation system 
of predominant subtypes for survival and recurrence has been 
investigated in several studies.9–12,29–31 However, the prob-
lem with histologic subtyping, subsequent tumor scoring or 
grading, and consequent prognosis prediction for lung ade-
nocarcinomas is that subtyping is estimated mainly using a 
resected surgical specimen (whole tumor), not by using a core 
biopsy or cytologic material. Moreover, in cases of unresect-
able lung cancer, histopathologic information is solely based 
on small pieces of the specimen obtained via tumor biopsy. 
Furthermore, approximately 80% of patients with lung can-
cer have an unresectable tumor at the time of initial presenta-
tion.32 Therefore, it is desirable to predict patient prognosis 
using surrogate imaging biomarkers that could be substituted 
for a histopathologic scoring system.19
Different imaging features observed in adenocarcino-
mas may provide additional prognostic information, assuming 
that functional phenotypes reflect the underlying genotype.4 
The use of radiologic features to predict tumor behavior 
is particularly attractive because this can be done quickly 
and noninvasively at the time of diagnosis. In this study, we 
investigated the prognostic impact of imaging factors includ-
ing TDR on HRCT and SUVmax on PET/CT using several 
different types of analyses. Our results are consistent with 
several previous reports.33–42 Ohde et al.35 and Suzuki et al.36 
both found that the extent of GGO is an important prognostic 
factor, with a large area of GGO indicating a good progno-
sis in cases of adenocarcinoma. Although a GGO component 
is known to be closely associated with a pathologic lepidic 
growth component,43,44 other subtypes such as well-organized 
and well-differentiated acinar or papillary-predominant ade-
nocarcinomas were also seen as pure ground-glass nodules.45 
This suggests that a GGO component, which can be expressed 
as areas of TDR,20 may represent low tumor cellularity or a 
less aggressive tumor over the extent of pathologic invasion. 
TABLE 3. Multivariate Analyses of Overall and Disease-Free Survival (Cox Proportional Hazards Model)
Factor
Overall Survival Disease-Free Survival
HR (95% CI) p HR (95% CI) p
Model 1
  Age 1.035 (1.002–1.070) 0.040 1.012 (0.994–1.030) 0.190
  Sex 0.386 (0.193–0.771) 0.007 0.911 (0.652–1.274) 0.587
  pT 1.402 (0.747–2.630) 0.293 1.171 (0.976–1.406) 0.090
  pN 1.724 (1.189–2.552) 0.004 1.235 (0.992–1.538) 0.059
  Adjuvant therapy 0.447 (0.193–1.032) 0.059 0.106 (0.063–0.180) <0.001
  Subtype 1.145 (0.932–1.407) 0.197 0.967 (0.853–1.096) 0.599
  SUVmax 1.048 (1.026–1.071) <0.001 1.022 (0.995–1.049) 0.110
  TDR-2 1.402 (0.747–2.630) 0.293 1.242 (0.861–1.791) 0.246
Model 2
  Age 1.032 (0.999–1.066) 0.054 1.014 (0.997–1.031) 0.112
  Sex 0.375 (0.191–0.737) 0.004 0.964 (0.692–1.343) 0.828
  pT 1.371 (1.003–1.873) 0.048 1.180 (0.983–1.418) 0.077
  pN 1.726 (1.177–2.530) 0.005 1.186 (0.951–1.481) 0.131
  Adj Tx. 0.519 (0.227–1.189) 0.121 0.117 (0.069–0.197) <0.001
  Pattern group 1.886 (1.129–3.151) 0.015 1.359 (1.009–1.829) 0.044
  SUVmax 1.045 (1.021–1.070) <0.001 1.009 (0.976–1.044) 0.597
  TDR-2 1.321 (1.003–1.873) 0.038 1.201 (0.833–1.732) 0.327
TDR, tumor shadow disappearance rate; SUVmax, maximum standardized uptake value.
Bold numbers indicate signiﬁcant p values (<0.05).
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Therefore, as shown in our results, a GGO component or TDR 
itself might be an independent prognostic factor.
Similarly, it is well known that the SUVmax on PET is 
an important preoperative factor for predicting the pathologic 
malignant grade and prognosis in cases of lung adenocarci-
noma.38–41 In our study, SUVmax on PET represented an inde-
pendent signiﬁcant prognostic factor (p < 0.001) for OS on 
multivariate analysis as well. On the other hand, several stud-
ies have reported no correlation between survival and FDG 
uptake in primary NSCLC.20,46,47 A recent meta-analysis also 
failed to determine whether SUVmax is an independent prog-
nostic feature in patients with NSCLC.48 Although the reasons 
for discordant results are not clear, the heterogeneity of lung 
adenocarcinomas could be partly responsible. According to a 
study by Kadota et al.49, tumors with intermediate-grade his-
tology but a higher SUVmax had either high-grade histology 
as the second predominant pattern or a high mitotic count. 
Histologic cell type or the degree of tumor differentiation may 
have an effect on increased FDG uptake on PET, regardless 
of tumor size.20 Thus, the combination of histology and PET 
might be more helpful in reflecting the heterogeneity of ade-
nocarcinomas compared with histology alone.
In patients with stage I lung adenocarcinoma, histologic 
subtypes and radiologic features were found to provide addi-
tional prognostic information beyond TNM staging system. 
Even though the histologic subtype was not a signiﬁcant prog-
nostic predictor in patients with II or IIIA lung adenocarcino-
mas, imaging features including TDR-2 and SUVmax were 
found to maintain signiﬁcance for predicting OS.
The prognostic value of the new classiﬁcation system 
of predominant subtypes for survival and recurrence has been 
investigated in several studies.9–12,29–31 However, there have 
been no previous reports which have compared prognostica-
tion capabilities among CT, PET, and the new IASLC/ATS/
ERS classiﬁcation system for lung adenocarcinomas.
With respect to frequency of each subtype, several pre-
vious studies with large cohorts showed various frequencies 
of ﬁve predominant subtypes of invasive lung adenocarcino-
mas.9,10,12 The frequency of a papillary pattern showed the high-
est variation, ranging from 28% in a US cohort of 514 to 5% in a 
German cohort of 500. Warth et al.50 reported that interobserver 
variability for papillary patterns was higher when compared 
with the other patterns, and differences in pattern interpreta-
tion may be a source of variability.51 Another possible reason 
for differences in pattern frequency is different distributions 
of patterns in distinct geographical regions and ethnic back-
grounds10 and different distributions of stages among cohorts. 
The US cohort that included only stage I patients showed 2% 
micropapillary and 13% solid-predominant patterns, whereas 
German and Taiwanese cohorts with advanced stages III and 
IV patients demonstrated 7% and 20% micropapillary and 38% 
and 14% solid-predominant patterns, respectively. To the best 
of our knowledge, this is the ﬁrst large-scale Korean cohort 
study. In our cohort of 723 patients ranging from stages I to 
fIGURE 3. Nomogram for predict-
ing the probability of 3- and 6-year 
survival in lung adenocarcinoma 
patients. (Calculate a total point 
by adding points associated with 
seven risk factors [sex = 55 points, 
pattern group of acinar/papillary = 
23, pattern group of micropapillary/
solid = 55, T1b stage = 30, T2a stage 
= 53, T2b or T3 stage = 100, N1 
stage = 59, N2 stage = 74, SUVmax 
> 9.5 = 50, age > 62 = 34, TDR < 15 
= 12] and draw a vertical line from 
the calculated total point to identify 
predicted survival probability.) TDR, 
tumor shadow disappearance rate; 
SUVmax, maximum standardized 
uptake value.
fIGURE 4. Kaplan–Meier survival curve based on stratifica-
tion using total points assigned by the nomogram.
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IIIA, micropapillary and solid-predominant adenocarcinomas 
accounted for 3% and 16% of cases.
Our study was limited inherently by its retrospective 
design, which may have resulted in a selection bias. In addition, 
many other potentially useful prognostic variables such as per-
formance status, CEA levels, and molecular proﬁles could not 
be included in our analysis. Although the utilization of molecu-
lar proﬁles to guide patient management strategies holds great 
promise, currently these tools are expensive and, in many set-
tings, unavailable.4 However, our study, to the best of our knowl-
edge, is the largest cohort study to date that has analyzed the 
prognostic value of clinicopathologic and imaging parameters in 
patients with lung adenocarcinoma. Although our results were 
obtained from a large cohort of lung adenocarcinoma patients, 
further external validation cohort study might help support and 
verify the certainty and reproducibility of our results.
In conclusion, the results of our study demonstrate that 
many variables including histologic IASLC/ATS/ERS classi-
ﬁcation, TDR on CT, and SUVmax on PET/CT are potentially 
promising predictors of disease severity in patients with ade-
nocarcinoma, and may have a prognostic impact on OS and 
DFS. The results of our study may allow selection for further 
staging workup and facilitate appropriate therapeutic strate-
gies for patients with lung adenocarcinoma.
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